



Did you know...

The Express Scripts' National Preferred Formulary utilized by the Duke Commercial Pharmacy Benefit Plans (Duke Basic, Duke Select, Duke BCBS, Duke USA, and Duke Advantage) was updated with new exclusions on January 1, 2026. These exclusions will impact less than 1% of Duke covered lives.

What this means for providers, patients, and pharmacies...

Fifty new drugs will be excluded in favor of cost-effective alternatives. A full list of exclusions is available at [Duke.is/j/4dpx](https://duke.is/j/4dpx).

A few things to highlight:

- Several notable exclusions:
 - » Humalog VIALS are excluded—the Humalog PENS and biosimilar insulin lispro VIALS are both covered
 - » Actemra SC is excluded in favor of the biosimilar Tyenne SC
- Multi-source brand exclusions (listed below) will exclude the branded medication listed but the generic equivalent will be covered (Example - Brand Vyvanse is excluded but its generic lisdexamfetamine is covered).

Multi-Source Brand Exclusions

The generic equivalents of the following brand-name medications are covered on the National Preferred Formulary. FDA-approved generic medications meet strict standards and contain the same active ingredients as their corresponding brand-name medications; although, they may have a different appearance.

BRILINTA
ENDARI
OXTELLAR XR

PROLENSA
PROMACTA
REVLIMID

TASIGNA
THIOLA EC
VYVANSE

If the preferred alternative of a medication is not clinically appropriate for a patient, a provider or office staff member may call 1-800-753-2851 to request a clinical exception to cover the excluded product. The clinical rationale will be reviewed by Express Scripts and a coverage determination made accordingly.

This communication was approved by the PHMO Ambulatory Care Pharmacy Provider Workgroup. For more information, please contact Lee Jackson at Lee.Jackson@Duke.edu.